Company Search:
Advanced Search
Sponsored Links
UCB Sa Company Snapshot
UCB Sa operates in the Biological products exc. diagnostic sector. In addition to historical fundamental analyses, the complete report available to purchase compares UCB Sa with three other pharmaceutical manufacturers in Europe: Ipsen SA of FRANCE (2019 sales of 2.69 billion Euros [US$3.16 billion] of which 85% was Specialty Care), Lonza Group AG of SWITZERLAND (5.92 billion Swiss Francs [US$6.50 billion] of which 70% was Pharma&Biotech), and Grifols SA which is based in SPAIN (5.10 billion Euros [US$5.99 billion] of which 78% was Bioscience).

Sales Analysis. UCB Sa reported sales of 4.91 billion Euro (US$5.77 billion) for the year ending December of 2019. This represents an increase of 6.1% versus 2018, when the company's sales were 4.63 billion Euro. Sales at UCB Sa have increased during each of the previous five years (and since 2014, sales have increased a total of 47%). Sales of Briviact saw an increase that was more than double the company's growth rate: sales were up 55.6% in 2019, from 142.00 million Euro to 221.00 million Euro. UCB Sa also saw significant increases in sales in Cimzia (up 18.4% to 1.71 billion Euro) and Vimpat (up 20.3% to 1.32 billion Euro) and Other Products (up 36.2% to 440.00 million Euro) . Not all segments of UCB Sa experienced an increase in sales in 2019: sales of Keppra fell 2.5% to 770.00 million Euro. UCB Sa also experienced decreases in sales in Neupro (down 0.6% to 319.00 million Euro) .
Company ReportsSubscriptions
Looking For More?
Purchace an In-Depth Report
  Stock Performance Chart for UCB Sa
  Stock Data: Recent Stock Performance:
  Current Price (10/23/2020): 90.48
(Figures in Euros )
1 Week -4.3%   13 Weeks -7.5%  
4 Weeks -17.7%   52 Weeks 29.7%  
UCB Sa Key Data:
  Ticker: UCB Country: Belgium
  Exchanges: BRU Major Industry: Pharmaceuticals & Biotechnology
    Sub Industry: Biological Products Exc. Diagnostic
  2019 Sales 4,913,000,000
(Year Ending Jan 2020).
Employees: 7,606
  Currency: Euros Market Cap: 17,111,522,588
  Fiscal Yr Ends: December Shares Outstanding: 189,119,392
  Share Type: Actions Ordinaires Closely Held Shares: 73,819,520
Feedback | Terms and Conditions | Privacy Policy | Site Index
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.